Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus GG

What does the research say about Lactobacillus rhamnosus GG?

2 health outcomes synthesised

Research on Lactobacillus rhamnosus GG spans 2 health outcomes, with the strongest evidence focused on reducing the duration of diarrhea in children. Across 3 studies, findings are mixed but predominantly show benefit, particularly at a dose of ≥10^10 CFU/day. The evidence base is small and considered preliminary, with no high-strength conclusions available.

Strongest evidence: Both outcomes have low evidence strength due to small study numbers (3 each). For reduced duration of diarrhea in children with acute diarrhea or gastroenteritis, 2 of 3 studies report beneficial effects, though one large RCT found no significant effect. The effective dose is ≥10^10 CFU/day, but effect sizes are mixed.

Mixed or weaker evidence: Improved health-related quality of life shows beneficial effects in 2 of 3 studies (children with ADHD), with a third neutral trial in adults with ulcerative colitis. Effect sizes are small to moderate. No effective dose is consistently reported, limiting generalizability.

Effective dose patterns: Only the diarrhea outcome provides a clear dose (≥10^10 CFU/day). The quality-of-life studies lack dose information, so no cross-outcome dose convergence is evident.

Population insights: Both outcomes predominantly involve children—those with acute diarrhea or ADHD. The quality-of-life benefit may not generalize to adults or other conditions, as highlighted by a neutral trial in adults with ulcerative colitis.

Notable caveats: Both syntheses caution that evidence is small (3 studies each) and conclusions are preliminary. Effect sizes vary widely, and one large high-quality RCT for diarrhea found no significant effect. For quality of life, study durations (median 28 days) may be insufficient, and dose data are missing.

Frequently asked

  • What is Lactobacillus rhamnosus GG good for according to research?
    Research suggests it may help reduce the duration of diarrhea in children with acute gastroenteritis, with 2 out of 3 studies showing benefit. It may also improve health-related quality of life in children with ADHD, though evidence is limited and preliminary.
  • What dose of Lactobacillus rhamnosus GG is typically used in studies?
    For reducing diarrhea duration, studies used doses of ≥10^10 CFU/day. For other outcomes, dose information is often not reported, making it unclear what amount is effective.
  • Who benefits most from Lactobacillus rhamnosus GG?
    Current evidence points to children—those with acute diarrhea or ADHD. Benefits have not been demonstrated in adults or other populations; for example, a small trial in adults with ulcerative colitis found no effect on quality of life.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus GG?
    Yes, the evidence base is small (only 3 studies per outcome) and considered preliminary. One large high-quality RCT for diarrhea found no significant effect, and effect sizes vary. Dose and study duration inconsistencies also limit conclusions.
  • Does Lactobacillus rhamnosus GG help with reducing diarrhea duration?
    Two of three studies show beneficial effects in children with acute diarrhea, particularly at doses of ≥10^10 CFU/day. However, a large RCT found no significant difference, and overall evidence strength is low.
  • Does Lactobacillus rhamnosus GG improve quality of life?
    Two of three studies report improvements in health-related quality of life for children with ADHD, with small to moderate effects. One neutral trial in adults with ulcerative colitis suggests the effect may not generalize. Evidence is low strength.

Safety profile

10 studies reporting safety data2 serious adverse events

Across 10 clinical studies, Lactobacillus rhamnosus GG was generally described as well tolerated, with 8 studies providing unquantified tolerability mentions and 2 studies reporting no significant differences in specific adverse events (death and bacterial cholangitis) compared to placebo. Two studies flagged serious adverse events (including risk of severe infections and antibiotic resistance gene transfer) in immunocompromised or critically ill populations, though no event showed a statistically significant increase versus control.

Caveats: Most studies were not primarily designed to assess safety, and the evidence includes studies in specific patient populations (e.g., liver disease, cow's milk allergy) where generalizability may be limited. Rare adverse events may be underdetected, particularly in immunocompromised individuals, and long-term safety data remain sparse.

Most-studied combinations with Lactobacillus rhamnosus GG

most supplement research is combination research
Also studied with:Saccharomyces boulardii (2), Lactobacillus reuteri DSM 17938 (4), Vitamin D (2), saccharomyces boulardii (2)
Back to top